Revisiting the 2010 Referred Sympathetic Pain Map: The Original Clinical, Pathophysiological, and Anatomical Documentation of Bottom-Up Nociplastic Pain.

This article examines 16 years of independent research that has converged on the descriptions made in the 2010 article, "Introduction to a Referred Sympathetic Pain Map." Although it predated the formal definition of bottom-up nociplastic pain, the original article's descriptions align retrospectively with this concept. Accordingly, the original map has been redesignated the Bottom-Up Nociplastic Pain Map (MAP), and this term is used throughout this article. The MAP is superficially and technically reminiscent of the dermatomal map, segmented into body regions based on symptom relief following selective nerve root and dorsal root ganglion (DRG) procedures. The MAP was defined using established interventional pain-mapping techniques: selective nerve root procedures and careful pre- and post-procedural mapping. The methodology used to develop the MAP was never novel. On the other hand, in 2010, the article’s physiological description of a third pain mechanism modulating secondary fibromyalgia and related conditions was without precedent, with specific descriptions, such as pulsed radiofrequency of the T5 dorsal root ganglion relieving diffuse arm and leg pain, directly contradicting basic neuroanatomy, pain physiology, and fibromyalgia. For that reason, the original description was published in Practical Pain Management, a non-peer-reviewed, non-indexed trade publication. In 2017, the International Association for the Study of Pain (IASP) formally recognized and defined nociplastic pain as a third mechanistic category of pain, validating the MAP's central premise. Beyond fitting within the intentionally broad IASP definition, the MAP article provided an organized, reproducible, and anatomically localizable model of bottom-up nociplastic pain. Also, beyond IASP’s original description, the MAP article described core pathophysiological features of bottom-up nociplastic pain, derived entirely from observations made during the MAP's development and refinement, independent of prevailing medical models. These included describing the bottom-up third mechanism of pain as an aberrant neuroinflammatory phenomenon modulated by dorsal root ganglia, and attributing the underlying pathophysiology to aberrant DRG-sympathetic coupling - descriptions made seven years before IASP formally described nociplastic pain and departing sharply from accepted clinical understanding in 2010. Sixteen years later, the core concepts from the 2010 article have been established across multiple converging domains of pain and neurophysiological research - research that increasingly aligns with the broader framework originally described in the MAP article. The breadth, specificity, and accuracy of these once unprecedented observations are unlikely to be coincidental and provide a substantial basis for formal investigation. Despite these research advances, bottom-up nociplastic pain still lacks a unifying clinical framework that ties its findings into a coherent mechanism. The MAP, if confirmed, will fill this gap by integrating converging lines of evidence into a single clinical framework that spans from an anatomical modulator to the resolution of the nociplastic symptom complex and advances in the diagnosis and treatment of bottom-up nociplastic pain.